维普期刊资源整合服务平台（V6.5）

62篇 您的检索式：作者名="bachet JB"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Would healing of the nasal and paranasal mucosa: a review 显示文摘	Watelet JB Bachet C Gevaert P	2002	Am J Rhi- hal2002，16，2：	1
2	Sonic hedgehog and Glil expression predict outcome in resected pancreatic adenocarcinoma 显示文摘	Mar6chal R Bachet JB Calomme A	2015	Clin Cancer Res2015，21，5：	1
3	KRAS mutations as an in- dependent prognostic factor in patients with advanced colorectal cancer treated with eetuximab 显示文摘	Lievre A Bachet JB Boige V	2008	J Clin Oncol2008，26，：	1
4	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab 显示文摘	Lievre A Bachet JB Boige V	2008	J Clin Oncol2008，26，：	1
5	KRAS mutationstatus is predictive of response to cetuximab therapy in colorectalcancer 显示文摘	LlfcVRE A BACHET JB LE CORRE D	2006	Cancer Res2006，66，8：	1
6	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab 显示文摘	Lievre A Bachet JB Boige V	2008	J Clin Oncol2008，26，3：	1
7	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer 显示文摘	Lievre A Bachet JB Le Corre D	2006	Cancer Res2006，66，8：	1
8	gastrointestinal stromal tumour(GIST) and germline mutation of KIT exon 133 显示文摘	Bachet JB Landi B Laurent-Puig P et aL Diagnosis prognosis and treatment of patients with	2013	Eur J Cancer2013，132，16：	1
9	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab显示文摘	Lievre A Bachet JB Boige V	2008	J Clin Oncol2008，26，3：	1
10	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer 显示文摘	Lievre A bachet JB Le Corre D	2006	Cancer Res2006，66，：	1
11	KRAS mutations as an in- dependent prognostic factor in patients with advanced colorec- tal cancer treated with cetuximab 显示文摘	Lievre A Bachet JB Boige V	2008	J Clin Oncol2008，26，3：	1
12	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab显示文摘	Lièvre A Bachet JB Boige V		0，，03：	1
13	StageⅡand stageⅢcolon cancer:treatment advances and future directions显示文摘	Rousseau B Chibaudel B Bachet JB	2010	Cancer J2010，16，3：	1
14	K-Ras mutation status is predictive of response to cetuximab therapy in colorectal cancer 显示文摘	Lievre A Bachet JB Le Corre D	2006	Cancer Res2006，66，8：	1
15	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab 显示文摘	Lievre A Bachet JB Boige V	2008	J Clin Oncol2008，26，3：	1
16	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer 显示文摘	Lievre A Bachet JB Le Cone D	2006	Cancer Res2006，66，8：	1
17	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with Cetuximab显示文摘	Lièvre A Bachet JB Boige V	2008	J Clin Oncol2008，26，3：	1
18	Levels of gemcitabine tramsport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma显示文摘	Maréchal R Bachet JB Mackey JR	2012	Gastroenterology2012，143，3：	1
19	S100A2 is a predictive bio- marker of adjuvant therapy benefit in pancreatic adenocarcinoma显示文摘	Bachet JB Marechal R Demetter P	2013	Eur J Cancer2013，49，12：	1
20	KRAS nmtations as an indepen- dent prognostic factor in patients with advanced colorectal cancer treated with cettvdmeb显示文摘	Lievre A Bachet JB Boige V et -1	2008	J Clin Oncol2008，26，3：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示